8-K - First Tracks Biotherapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

First Tracks Biotherapeutics, Inc. announced SEC effectiveness of its Form 10 registration statement for the spin-off from AnaptysBio, Inc., with distribution of one TRAX share per ANAB share on April 20, 2026.

Key Takeaways

1Registration Statement on Form 10 declared effective April 1, 2026, enabling spin-off of First Tracks Biotherapeutics from AnaptysBio.

2Spin-off record date April 6, 2026; distribution effective April 20, 2026 at 12:01 a.m. New York time.

3TRAX when-issued trading under TRAXv starts April 6, 2026; regular way on Nasdaq under TRAX from April 20, 2026.

4Concurrent private placement: 5,791,478 primary shares at $13.81/share for ~$80 million gross proceeds.

5First Tracks Bio to launch with ~$180 million cash; focus on antibody therapies including ANB033, rosnilimab, ANB101.

6Spin-off is taxable for U.S. federal income tax purposes.

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth

Regulation Fd

9.01

| Financial Statements and Exhibits. | |---|---| (d) Exhibits Exhibit No.: 99.1 | Description: Information Statement of First Tracks Biotherapeutics, Inc., date

Exhibits Only

Source Document

Transaction Details

Acquisition / Disposition

Target: First Tracks Biotherapeutics, Inc. (biopharma operations from AnaptysBio)
Consideration: Pro rata distribution of all common stock (1:1 ratio)
Structure: Spin-off via Form 10 registration

•Record Date: April 6, 2026
•Distribution Date: April 20, 2026
•Subject to conditions including Nasdaq listing

Exhibits (2)

8-K

99.1

EX-99.1